Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ElementoLab
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ElementoLab
-
Olivier Elemento proslijedio/la je Tweet
GlaxoSmithKline CEO Emma Walmsley is triggering a New GSK R&D makeover, while shedding dermatologyhttps://endpts.com/glaxosmithkline-ceo-emma-walmsley-is-triggering-a-new-gsk-rd-makeover-while-shedding-dermatology/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Genome-wide loss-of-function screen leads to identification of impaired death receptor signalling in ALL as a mechanism that leads to the failure of CD19-targeted CAR T cell therapy: https://cancerdiscovery.aacrjournals.org/content/early/2020/01/24/2159-8290.CD-19-0813 …
#ImmunoOnc#hemeonc#leusmHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
1. Four years ago, when we launched our first bio fund, the idea that software would make an impact in drug discovery sounded like science fiction; the idea it could transform the patient experience in healthcare a fool’s errand.https://a16z.com/2020/02/04/bio-fund-iii-announcement/ …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Claims of an AI-generated drug hitting the clinic. What does this mean for drug discovery?https://blogs.sciencemag.org/pipeline/archives/2020/01/31/another-ai-generated-drug …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Another example of
#biopharma responding to an industry “call to arms” in the fight against#coronavirus #2019-nCoV.... and another reason to be proud and thankful of America’s#biopharma industry! Thank you,@Regeneronhttps://endpts.com/regeneron-joins-the-hunt-for-antibodies-to-fight-a-brewing-pandemic-as-researchers-whip-up-new-trials-for-antivirals/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
The
@EngIPM@WeillCornell is hiring! We have openings for Research Specialists, PostDoc Fellows, Bioinformatics Analysts, and more! Start or expand your career with us and work with global leaders in#PrecisionMedicine#AI#BigData#Genomics and more: https://eipm.weill.cornell.edu/about/career-opportunities/ …pic.twitter.com/TV17mlR9nW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
We hope to see you Friday for the Fourth Annual
#AI Health Hackathon (with cash prizes)! An unforgettable learning & networking opportunity hosted by@EngIPM@cornell_tech@HSpecialSurgery@sloan_kettering@Hunter_College with@JNJNews! Learn more: https://health2020.splashthat.com pic.twitter.com/jFqTWkchpt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Great commentary from
@EngIPM Member Melissa B. Davis, Ph.D. (@MeliD32)@WeillCornell on#WorldCancerDay
and the need for more inclusive participation by minorities and underserved populations in clinical trials.
#breastcancerhttps://twitter.com/WeillCornell/status/1224762914088923137 …
0:53Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
"Neither a higher dose nor longer treatment schedule prolonged survival...," for men with heavily pretreated mCRPC, reported
@EngIPM Clinical Director Cora N. Sternberg, M.D. (@cnsternberg) in a recent@medpagetoday article.#ProstateCancer https://www.medpagetoday.com/hematologyoncology/prostatecancer/84677 …pic.twitter.com/CkdXV13vlZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
“This technology has sprinted forward at an incredible speed...with no clear consensus on what is best,” said
@EngIPM Member Nasser Altorki, M.D.@WeillCornell on new ASCO guidelines addressing surveillance of lung cancer. https://www.ascopost.com/news/february-2020/asco-guideline-addresses-surveillance-of-lung-cancer-after-curative-intent-therapy/ …pic.twitter.com/eIQQOxZXJc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
A Viewpoint by
@Dr_R_Kurzrock,@DrHKantarjian,@akesselheim &@Esigal on 'New drug approvals in oncology' is now live online: https://www.nature.com/articles/s41571-019-0313-2?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NRRJ_2_SJB_nrclinonc_editorial_socialposts …#caxtx#hpeoncpic.twitter.com/X0ynz4OnE9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Join us for the next Institute for Computational Biomedicine Seminar, "Notch-mutated Cancer Genomes in 3D," by R. Babak Faryabi, PhD from the
@PennEpiInst@PennMedicine. Hosted by@EngIPM's Olivier Elemento, PhD (@ElementoLab). February 24th, 11 AM, 1300 York Ave., Room LC-504pic.twitter.com/kUM9FhazaD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
On
#WorldCancerDay
we asked #WCM experts: “What is the bravest thing we can do about cancer?” Dr. Melissa B. Davis (@MeliD32) of@EngIPM wants to find ways to make cancer treatment affordable.pic.twitter.com/HIeQXF5SuZHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
On
#WorldCancerDay
we asked #WCM experts: “What is the bravest thing we can do about cancer?” Dr. Onyinye Balogun (@GlobalRadOnc) of#WCMRadOnc &@nyphospital says it comes down to being honest with your patients.pic.twitter.com/RSpu7nigU1Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Sad to hear of the passing of Dr Phil Leder, from 1st generation college student to founder of Dept of Genetics
@harvardmed,@LaskerFDN award, National Medal of Science https://buff.ly/31p6cXu https://buff.ly/394C0nd pic.twitter.com/PpVdXkgMtt
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
On
#WorldCancerDay
we asked #WCM experts: “What is the bravest thing we can do about cancer?” Dr. Olivier Elemento (@ElementoLab) of@EngIPM reminds us that the patients are truly the brave ones in the fight against#cancer.pic.twitter.com/UoatiPyTaEHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Q&A with Jorge Conde as Andreessen Horowitz launches $750M bio fund IIIhttps://endpts.com/qa-with-jorge-conde-as-andreessen-horowitz-launches-750m-bio-fund-iii/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excellent thread - thanks
@HorsingJig !https://twitter.com/horsingjig/status/1224341449627635718 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Gr8 new
#TechTonics feat@SeanKhozin, who shares his captivating journey, from fleeing Iran after Revolution to pursuing medicine+technology in the U.S., recently@US_FDA & now at@JNJNews - all while maintaining his passion for music. https://buff.ly/31mlOet@VentureValkyriepic.twitter.com/JVbC7l9iRh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Olivier Elemento proslijedio/la je Tweet
Immunotherapy for
#cancer needs refinement and this perspective makes a solid case that single-cell#genomics can help us get there https://www.nature.com/articles/s41591-019-0736-4 …@NatureMedicine by@IdoYofe@DahanLab@IdoAmitLab@WeizmannSciencepic.twitter.com/PWrbvOkx7R
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.